Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline

PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.

Download Full-text

Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature

The Journal of Urology ◽

10.1016/j.juro.2015.04.103 ◽

2015 ◽

Vol 194 (4) ◽

pp. 983-988 ◽

Cited By ~ 56

Author(s):

Guillaume Ploussard ◽

Christophe Almeras ◽

Alberto Briganti ◽

Gianluca Giannarini ◽

Christophe Hennequin ◽

...

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Local Treatment ◽

Review Of The Literature

Download Full-text

Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?

Seminars in Oncology ◽

10.1053/j.seminoncol.2013.04.008 ◽

2013 ◽

Vol 40 (3) ◽

pp. 375-392 ◽

Cited By ~ 23

Author(s):

Michael J. Morris ◽

Karen A. Autio ◽

Ethan M. Basch ◽

Daniel C. Danila ◽

Steven Larson ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcomes ◽

Advanced Prostate Cancer ◽

Imaging Modalities

Download Full-text

Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run

Radiotherapy and Oncology ◽

10.1016/j.radonc.2004.08.005 ◽

2004 ◽

Vol 73 (1) ◽

pp. 11-20 ◽

Cited By ~ 19

Author(s):

Vassilis E. Kouloulias ◽

Jean-Yves Giraud ◽

Bernard J. Davis ◽

Andrée Dusserre ◽

Alfredo Zurlo ◽

...

Keyword(s):

Prostate Cancer ◽

Quality Assurance ◽

Radiation Therapy ◽

Adjuvant Treatment ◽

Advanced Prostate Cancer ◽

Locally Advanced ◽

Optimal Combination ◽

Phase Iii ◽

Locally Advanced Prostate Cancer ◽

Phase Iii Study

Download Full-text

Decision-making support among racial and ethnic minorities diagnosed with breast or prostate cancer: A systematic review of the literature

Patient Education and Counseling ◽

10.1016/j.pec.2021.09.012 ◽

2021 ◽

Author(s):

Antonio P. DeRosa ◽

Yendé Grell ◽

Dominic Razon ◽

Alia Komsany ◽

Laura C. Pinheiro ◽

...

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Decision Making ◽

Ethnic Minorities ◽

Review Of The Literature ◽

Racial And Ethnic Minorities ◽

Decision Making Support

Download Full-text

The emerging role of whole-body magnetic resonance imaging in advanced prostate cancer

Minerva Urology and Nephrology ◽

10.23736/s2724-6051.21.04344-7 ◽

2021 ◽

Vol 73 (2) ◽

Author(s):

Andra CURCEAN ◽

Filippo RUSSO ◽

Pasquale RESCIGNO ◽

Nina TUNARIU

Keyword(s):

Magnetic Resonance Imaging ◽

Prostate Cancer ◽

Magnetic Resonance ◽

Advanced Prostate Cancer ◽

Whole Body ◽

Resonance Imaging ◽

Body Magnetic Resonance Imaging

Download Full-text

Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155218808080 ◽

2018 ◽

Vol 25 (4) ◽

pp. 903-917 ◽

Cited By ~ 1

Author(s):

Neda Khalili ◽

Mahsa Keshavarz-Fathi ◽

Sepideh Shahkarami ◽

Armin Hirbod-Mobarakeh ◽

Nima Rezaei

Keyword(s):

Prostate Cancer ◽

Systematic Review ◽

Monoclonal Antibodies ◽

Advanced Prostate Cancer ◽

Search Strategy ◽

Specific Immunotherapy ◽

Therapeutic Option ◽

Grey Literature ◽

Statistical Heterogeneity ◽

Specific Antigens

Introduction Treatment of metastatic castration-resistant prostate cancer with conventional therapies is still not successful. Therefore, application of novel biological approaches such as immunotherapy, which appears to be more effective and less toxic, is necessary. Monoclonal antibodies against cancer specific antigens are a kind of immunotherapy that have been approved for specific types of cancer and are being investigated for prostate cancer as well. The aim of this review was to assess the effectiveness and safety of monoclonal antibodies for treatment of advanced prostate cancer. Method According to the search strategy stated in our systematic review protocol, Scopus, Medline, TRIP, CENTRAL, ProQuest, DART and OpenGrey databases were searched. Data collection and quality assessment were done independently by two authors and any disagreements between the collected data were resolved by a third author. A meta-analysis was not feasible as there was a considerable statistical heterogeneity among the trials. Hence, this review was limited to a narrative analysis of the included studies. Results We found 9756 references by applying search strategy in 4 databases of journal articles and 3 databases of grey literature. We then discarded 3957 duplicate citations using Endnote software and 5143 articles due to obvious irrelevancy of their topics in primary screening. In secondary screening of 656 fulltexts, we excluded 538 articles, and finally included 12 trials in this systematic review, updated on 23 June 2017. The overall quality of the studies was fair. In general, results of this systematic review show promising advances in the treatment of prostate cancer patients with monoclonal antibodies against prostate-specific antigens with regard to PSA/disease response. Some of the studies reported pain relief after treatment as well. Conclusion Currently, the role of immunotherapy in the treatment of advanced prostate cancer still remains debated. Although passive specific immunotherapy could be offered as a novel therapeutic option in the coming years, patients should be informed about the risks and benefits of this therapy. One of the obstacles in this review was the lack of adequate assessment of survival-related endpoints reported in the included studies. Our study provides support for further research in this field.

Download Full-text